235 related articles for article (PubMed ID: 16343243)
1. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
Boyce EA; Kohn EC
Int J Gynecol Cancer; 2005; 15 Suppl 3():266-73. PubMed ID: 16343243
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer: can proteomics give new insights for therapy and diagnosis?
Toss A; De Matteis E; Rossi E; Casa LD; Iannone A; Federico M; Cortesi L
Int J Mol Sci; 2013 Apr; 14(4):8271-90. PubMed ID: 23591842
[TBL] [Abstract][Full Text] [Related]
3. [Identification of new ovarian cancer biomarkers with proteomic analyses--the diagnostic tool of the future?].
Petri AL; Høgdall E; Engelholm SA; Christensen IJ; Kjaer SK; Høgdall CK
Ugeskr Laeger; 2007 Aug; 169(33):2614-9. PubMed ID: 17725906
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer in the proteomics era.
Annunziata CM; Azad N; Dhamoon AS; Whiteley G; Kohn EC
Int J Gynecol Cancer; 2008; 18 Suppl 1():1-6. PubMed ID: 18336391
[TBL] [Abstract][Full Text] [Related]
5. Plasma proteomic pattern as biomarkers for ovarian cancer.
Lin YW; Lin CY; Lai HC; Chiou JY; Chang CC; Yu MH; Chu TY
Int J Gynecol Cancer; 2006; 16 Suppl 1():139-46. PubMed ID: 16515582
[TBL] [Abstract][Full Text] [Related]
6. Serum proteomic patterns for ovarian cancer monitoring.
Helleman J; van der Vlies D; Jansen MP; Luider TM; van der Burg ME; Stoter G; Berns EM
Int J Gynecol Cancer; 2008; 18(5):985-95. PubMed ID: 18028381
[TBL] [Abstract][Full Text] [Related]
7. Novel proteomic technologies to address gaps in pre-clinical ovarian cancer biomarker discovery efforts.
Jordan HA; Thomas SN
Expert Rev Proteomics; 2023; 20(12):439-450. PubMed ID: 38116719
[TBL] [Abstract][Full Text] [Related]
8. Investigation of early and advanced stages in ovarian cancer using human plasma by differential scanning calorimetry and mass spectrometry.
Kim NA; Jin JH; Kim KH; Lim DG; Cheong H; Kim YH; Ju W; Kim SC; Jeong SH
Arch Pharm Res; 2016 May; 39(5):668-76. PubMed ID: 27002828
[TBL] [Abstract][Full Text] [Related]
9. [Proteomics and biomarkers for detection of ovarian cancer].
Kacerovský M; Tambor V; Lenco J; Tosner J
Ceska Gynekol; 2009 Jun; 74(3):163-70. PubMed ID: 19642513
[TBL] [Abstract][Full Text] [Related]
10. Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer.
Woong-Shick A; Sung-Pil P; Su-Mi B; Joon-Mo L; Sung-Eun N; Gye-Hyun N; Young-Lae C; Ho-Sun C; Heung-Jae J; Chong-Kook K; Young-Wan K; Byoung-Don H; Hyun-Sun J
Cancer Sci; 2005 Mar; 96(3):197-201. PubMed ID: 15771624
[TBL] [Abstract][Full Text] [Related]
11. Proteomic studies of early-stage and advanced ovarian cancer patients.
Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
[TBL] [Abstract][Full Text] [Related]
12. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer.
Tchabo NE; Liel MS; Kohn EC
Am J Pharmacogenomics; 2005; 5(3):141-8. PubMed ID: 15952868
[TBL] [Abstract][Full Text] [Related]
13. Proteomic profiling in ovarian cancer.
Kim G; Minig L; Kohn EC
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2(Suppl 2):S2-6. PubMed ID: 19955909
[TBL] [Abstract][Full Text] [Related]
14. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
[TBL] [Abstract][Full Text] [Related]
15. [Molecular diagnostics of ovarian cancer using proteome techniques].
Vlasova MA; Moshkovskiĭ SA; Safarova MP; Makarov OV; Archakov AI
Biomed Khim; 2005; 51(4):367-83. PubMed ID: 16223028
[TBL] [Abstract][Full Text] [Related]
16. Clinical potential of proteomics in the diagnosis of ovarian cancer.
Ardekani AM; Liotta LA; Petricoin EF
Expert Rev Mol Diagn; 2002 Jul; 2(4):312-20. PubMed ID: 12138495
[TBL] [Abstract][Full Text] [Related]
17. Biomarker discovery in ovarian cancer.
Tung CS; Wong KK; Mok SC
Womens Health (Lond); 2008 Jan; 4():27-40. PubMed ID: 19072449
[TBL] [Abstract][Full Text] [Related]
18. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations.
Diamandis EP
Mol Cell Proteomics; 2004 Apr; 3(4):367-78. PubMed ID: 14990683
[TBL] [Abstract][Full Text] [Related]
20. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics.
Simpkins F; Czechowicz JA; Liotta L; Kohn EC
Pharmacogenomics; 2005 Sep; 6(6):647-53. PubMed ID: 16143004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
